Excellent data tables from Barclays ahead of #ASCO24 . 1st line gastric cancer, 3rd line colorectal, PRAME therapies ( $IMTX, $IMCR)

Yüksel Ürün Shilpa Gupta Omar Abdihamid, Oncologist ASCO FCOI: bit.ly/3KkgH Jacob J. Adashek, DO ylt Tom Powles Matt Galsky Umang Swami Andrea Necchi joaquim bellmunt Guru P. Sonpavde, MD Petros Grivas Andrea Apolo, M.D. Neeraj Agarwal, MD, FASCO Nearly doubling progression-free survival and improving QoL, EV+P in the EV-302 trial is a game-changer for urothelial cancer. #ASCO24 #BladderCancer

Thrilled to present our interim results from the SURE 01 study with preoperative sacituzumab govitecan in patients with MIBC at @ASCO2024!!!

Keynote 522 . Pembrolizumab in early stage TNBC shows OS benifit. We will love to see the OS data in with those with PCR and those who did not achieve PCR and Based Upon RCB . Remember the EFS benifit was maximum in RCB -2 and RCB -3 had infact detrimental EFS . Sara Tolaney

Important Overall Survival results in KEYNOTE-522.
Important advance for our patients with #early TNBC, but we are still waiting biomarker analyses for this trial... FDA Oncology OncoAlert Merck #bcsm #research

ASCO 2024: #bladdercancer Top 3 Abstract Recommendations IMO from AdventHealth Central Florida UCF UCF Medicine - prac.co/l/24kd6p6e via PracticeUpdate Matt Galsky Michiel van der Heijden Shilpa Gupta Tom Powles

This is really important and so encouraging to see. Especially in #HER -2 and #TNBC , it's clear DDFS is a surrogate for OS.

Now we have to figure if we can give immunotherapy with less chemo than KN522. This can be a tough regimen for many.

#bcsm

⚡️ On European Urology - Cabozantinib + nivolumab shows promising results in non–clear cell renal cell carcinoma. With a 48% response rate and median overall survival of 28 months, this combination offers a potential new treatment option. No new safety concerns were observed.

Today’s press release by Merck:
KEYNOTE-522 met its overall survival endpoint in high-risk early TNBC

Excellent news for our #breastcancer patients

OncoAlert

merck.com/news/merck-ann…

Mixed response to the first-line treatment of KRAS G12C inhibitor, sotorasib, in 🫁 NSCLC: A brief report.
#Immunoenvironment
#sequencing
🔻
doi.org/10.1002/ccr3.8…

⏰NOW OUT‼️ #ASCO24 Abstracts
🔥#8501 ICARUS-LUNG01: Datopotomab deruxtecan in previously treated NSCLC
🎙️d.planchard
🎯ORR 28.0%, mPFS 3.6mo. TRAEs ≥G3 25%. Stomatitis 49%
✅Phase II
✅Primary: ORR
✅NCT04940325
📈TROPION-Lung01 (NCT04656652)
#LCSM OncoAlert ASCO

⏰NOW OUT‼️ #ASCO24 Abstracts
🔥#103 LUMINOSITY: Telisotuzumab vedotin c-Met–overexpressing non-sq EGFR wildtype NSCLC
🎙️D. Ross Camidge
🎯ORR 34.6%, mDOR 9.0mo, mPFS 5.7mo. TRAEs neuropathy 30%, edema 16%, fatigue 14%
✅Phase II
✅Primary: ORR
✅NCT03539536
#LCSM OncoAlert ASCO

🚨KN-522 positive OS announcement👇

OncoAlert

⏰NOW OUT‼️ #ASCO24 Abstracts
🔥#8504 MARIPOSA: Amivantamab plus lazertinib vs osimertinib in 1st-line EGFRm NSCLC with biomarkers of high-risk disease
🎙️Enriqueta Felip
🎯TP53 co-mutation mPFS: Ami+Laz 18.2mo vs. Osi 12.9mo
✅Phase III
✅NCT04487080
#LCSM OncoAlert ASCO

My top 7 #ASCO24 abstracts to watch for #mmsm

Will have more details on those once presented/published- those are initial thoughts that may evolve according to more data

There are more interesting data will highlight during the meeting

ASCO

🧵

very important news! Overall Survival seen in KN522!!!

Press release: the addition of pembro to neoadjuvant chemo improves OS in stage II-III TNBC.

Tremendous news for one of the greatest unmet needs in breast oncology.

Next step: tailoring strategies to preserve the benefit while minimizing IO-toxicities.

merck.com/news/merck-ann…

🏮Beamion LUNG-1: Zongertinib in pts w/ HER2 aberration + (ph 1a) & HER2 mutation + mNSCLC (ph 1b)

Ph 1a
▫️36 pts w/ NSCLC
▫️ORR 58%; DCR 97%
Ph 1b
▫️ 23 pts
▫️ORR 74%; DCR 91%
▫️AEs: diarrhea, rash

Emerging TKIs in the #HER2 space. ASCO OncoAlert #ASCO24 #lcsm

⏰NOW OUT‼️ #ASCO24 Abstracts
🔥#8008 GASTO-1091: Neo-adj Nivo + Chemo and concurrent hypofractionated chemoradiotherapy with or without Nivo consolidation
🎙️Dr. Hui Liu
🎯Nivo consolidation: HR 0.49 (95%CI 0.31-0.79)
✅Phase II
✅Primary: PFS
✅NCT04085250
#LCSM OncoAlert ASCO

Dr Kastritis discusses Dara-based Rx for stage 3b AL #amyloidosis . Feasible, but not a home run. Still plenty of early deaths (perhaps fewer than historically). Lots of room to add disease modifying Rx: antifibril
moAbs? LC stabilizers? 1/The International Society Of Amyloidosis #ISA2024